Current Status of Dengue Therapeutics Research and Development

@article{Low2017CurrentSO,
  title={Current Status of Dengue Therapeutics Research and Development},
  author={Jenny Guek-Hong Low and Eng Eong Ooi and Subhash G. Vasudevan},
  journal={The Journal of Infectious Diseases},
  year={2017},
  volume={215},
  pages={S96 - S102}
}
Abstract Dengue is a significant global health problem. Even though a vaccine against dengue is now available, which is a notable achievement, its long-term protective efficacy against each of the 4 dengue virus serotypes remains to be definitively determined. Consequently, drugs directed at the viral targets or critical host mechanisms that can be used safely as prophylaxis or treatment to effectively ameliorate disease or reduce disease severity and fatalities are still needed to reduce the… 

Figures and Tables from this paper

Dengue Antiviral Development: A Continuing Journey.

In recent years, efforts to develop dengue therapeutics have focused on both repurposing approved drugs as well as discovery of new chemical entities that act via virus or host targeted mechanisms.

Dengue

Dengue: A Minireview

This work reviews DENV biology, epidemiology, transmission dynamics including circulating serotypes and genotypes, the immune response, the pathogenesis of the disease as well as updated diagnostic methods, treatments, vector control and vaccine developments.

Lessons Learned and Recent Advances in Dengue Research

Dengue is the most important arbovirus, many research have contributed to the diagnosis, management, prevention and control of this disease, which will be described in this chapter, for example: the

Current Trends and Limitations in Dengue Antiviral Research

Increase in structural insights into the dengue NS5 protein will accelerate drug discovery efforts focused on NS5 as an antiviral target, which is the largest and most conserved nonstructural protein encoded by flaviviruses.

A Multi-perspective Review of Dengue Research.

The importance of Natural chemical moieties like methionine-proline anilides, tetrapeptide aldehyde via Structure Activity Relationship studies and the drug candidates currently in the clinical trials that have the potential to solve this issue are explained.

Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication

This review elaborate the ribozymes, RNA interference, CRISPR, aptamer and morpholino strategies for the inhibition of DENV replication and discuss the challenges involved in utilizing such approaches.

A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.

A highly potent dengue virus inhibitor (JNJ-A07) that exerts nanomolar to picomolar activity against a panel of 21 clinical isolates that represent the natural genetic diversity of known genotypes and serotypes, thus revealing a previously undescribed mechanism of antiviral action.

Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate

The pathogenic roles of DENV NS1 in hemorrhage and vascular leakage are reviewed, and the possibility of using NS1 as a therapeutic target and vaccine candidate is discussed.

Bioethics of establishing a CHIM model for dengue vaccine development.

  • Anuradha RoseA. Sekhar
  • Medicine
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2019
...

References

SHOWING 1-10 OF 90 REFERENCES

Dengue Human Infection Models Supporting Drug Development

The merits of a dengue human infection model (DHIM) for drug development could allow experimentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using smaller sample sizes than trials that recruited patients with d Dengue in an endemic country.

Therapeutic antibodies as a treatment option for dengue fever

The strategies and technologies that can be adopted to develop antibodies for therapeutic applications are reviewed and the mechanism of antibody neutralization in the cells targeted by DENV that express Fc gamma receptor is discussed.

Dengue human infection model performance parameters.

  • T. Endy
  • Medicine
    The Journal of infectious diseases
  • 2014
A dengue human infection model (DHIM) will be an essential tool in developing potential d Dengue vaccines or antivirals and the potential performance parameters needed for a DHIM to support vaccine or antiviral candidates are discussed.

New insights into the immunopathology and control of dengue virus infection

Recent advances in the understanding of immunopathology, vaccine development and human monoclonal antibodies produced against dengue virus are outlined.

Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions

This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.

The Animal Models for Dengue Virus Infection

The development of small animal models such as mice for dengue virus infections is reviewed and the mechanisms involved in the pathogenesis of DHF/DSS remain poorly understood.

A Novel Inhibitor of Dengue Virus Replication That Targets the Capsid Protein

A novel small-molecule compound, ST-148, is described that is a potent inhibitor of all four serotypes of DENV in vitro and appears to interact with the DENV C protein and inhibits a distinct step of the viral replication cycle.

Experimental therapies for yellow fever.

Characterization of the Mode of Action of a Potent Dengue Virus Capsid Inhibitor

The mode of action of ST-148, a small-molecule capsid inhibitor with potent antiviral activity against all DV serotypes is investigated by using a combination of biochemical, virological, and imaging-based techniques to demonstrate that it stabilizes capsid protein self-interaction.
...